160729-91-9
Chemical Structure
HIV-IN-11
- CAS No.: 160729-91-9
- Formula:C38H47N5O5
- Molecular Weight:653.81
IUPAC Name: (S)-1-((2S,4R)-4-benzyl-2-hydroxy-5-(((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)amino)-5-oxopentyl)-N-(tert-butyl)-4-(furo[2,3-b]pyridin-5-ylmethyl)piperazine-2-carboxamide
InChIKey: UBUFVRJUGFJQSI-PPJSLLJVSA-N
SMILES: O=C([C@@H](C[C@@H](CN1[C@@H](CN(CC1)CC2=CN=C3OC=CC3=C2)C(NC(C)(C)C)=O)O)CC4=CC=CC=C4)N[C@@H]5[C@@H](CC6=C5C=CC=C6)O
Biological Activity: HIV-IN-11 is part of the hydroxylaminoglutaramide (HAPA) transition state isomeric series of HIV protease inhibitors and is a potent and selective inhibitor of HIV-1 protease. HIV-IN-11 competitively inhibits HIV-1 PR (Ki: 0.049 nM) and potently inhibits replication of HIV(IIIb)-infected MT4 lymphocytes at concentrations of 25.0-50.0 nM. HIV-IN-11 displays a longer half-life than indinavir sulfate in animal models and serves as a promising second-generation HIV protease inhibitor[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
HIV-IN-11 | HIV-IN-11 is part of the hydroxylaminoglutaramide (HAPA) transition state isomeric series of HIV protease inhibitors and is a potent and selective inhibitor of HIV-1 protease. HIV-IN-11 competitively inhibits HIV-1 PR (Ki: 0.049 nM) and potently inhibits replication of HIV(IIIb)-infected MT4 lymphocytes at concentrations of 25.0-50.0 nM. HIV-IN-11 displays a longer half-life than indinavir sulfate in animal models and serves as a promising second-generation HIV protease inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
